We are analyzing https://link.springer.com/article/10.1007/s00125-002-0901-y.

Title:
The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice | Diabetologia
Description:
Aims/hypothesis. Pro-inflammatory cytokines are increased during the active stages of Type I (insulin-dependent) diabetes mellitus. The aim of this study was to investigate the applicability of using a new anti-inflammatory compound, Lisofylline, to prevent diabetes in non-obese diabetic (NOD) mice. Lisofylline has previously been shown to block Th1 cell differentiation and to reduce IL-1β-induced dysfunction in rat islets. Methods. Lisofylline was added to isolated NOD islets in vitro, with or without IL-1β. Insulin secretion and DNA damage of the islets was assessed. Lisofylline was administered to female non-obese diabetic mice starting at 4, 7 and 17 weeks of age for 3 weeks. Cytokines and blood glucose concentrations were monitored. Histology and immunohistochemistry were carried out in pancreatic sections. Splenocytes isolated from donor mice were intravenously injected into immunodeficient NOD (NOD.scid) mice. Results. In vitro, Lisofylline preserved beta-cell insulin secretion and inhibited DNA damage of islets in the presence of IL-1β. In vivo, Lisofylline suppressed IFN-γ production, reduced the onset of insulitis and diabetes, and inhibited diabetes after transfer of splenocytes from Lisofylline-treated donors to NOD.scid recipients. However, cotransfer of splenocytes from both Lisofylline-treated and diabetic NOD donors did not suppress diabetes in recipient mice. Conclusion/interpretation. Lisofylline prevents the onset of autoimmune diabetes in NOD mice by a mechanism that does not seem to enhance the function of regulatory T cells, but could be associated with suppression of proinflammatory cytokines and reduction of cellular infiltration in islets. This study suggests that Lisofylline could have therapeutic benefits in preventing the onset of Type I diabetes.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Telecommunications
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

diabetes, lisofylline, article, mice, type, nod, privacy, cookies, diabetic, islets, content, information, publish, search, nonobese, data, journal, research, diabetologia, antiinflammatory, compound, prevents, august, download, yang, chen, cytokines, ilβ, insulin, splenocytes, onset, open, access, discover, endocrinology, function, optional, personal, parties, policy, find, track, published, cite, pdf, manuscript, mcduffie, nadler, explore, proinflammatory,

Topics {✒️}

reduce il-1β-induced dysfunction anti-inflammatory compound related subjects privacy choices/manage cookies socs1 reverses diabetes obese diabetic mice diabetic nod donors insulin secretion main content log pro-inflammatory cytokines european economic area blood glucose concentrations lisofylline-treated donors conditions privacy policy il-1β accepting optional cookies scope submit manuscript lisofylline prevents insulin-dependent isolated nod islets inhibited dna damage journal finder publish inhibited diabetes type increased plasmablasts enhance search search obese diabetic diabetes mellitus prevent diabetes suppress diabetes autoimmune diabetes nod mice article cite article yang lisofylline-treated privacy policy personal data immunodeficient nod nadler division books a information donor mice recipient mice optional cookies manage preferences dna damage endocrinology diabetes data protection essential cookies

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice
         description: Aims/hypothesis. Pro-inflammatory cytokines are increased during the active stages of Type I (insulin-dependent) diabetes mellitus. The aim of this study was to investigate the applicability of using a new anti-inflammatory compound, Lisofylline, to prevent diabetes in non-obese diabetic (NOD) mice. Lisofylline has previously been shown to block Th1 cell differentiation and to reduce IL-1β-induced dysfunction in rat islets. Methods. Lisofylline was added to isolated NOD islets in vitro, with or without IL-1β. Insulin secretion and DNA damage of the islets was assessed. Lisofylline was administered to female non-obese diabetic mice starting at 4, 7 and 17 weeks of age for 3 weeks. Cytokines and blood glucose concentrations were monitored. Histology and immunohistochemistry were carried out in pancreatic sections. Splenocytes isolated from donor mice were intravenously injected into immunodeficient NOD (NOD.scid) mice. Results. In vitro, Lisofylline preserved beta-cell insulin secretion and inhibited DNA damage of islets in the presence of IL-1β. In vivo, Lisofylline suppressed IFN-γ production, reduced the onset of insulitis and diabetes, and inhibited diabetes after transfer of splenocytes from Lisofylline-treated donors to NOD.scid recipients. However, cotransfer of splenocytes from both Lisofylline-treated and diabetic NOD donors did not suppress diabetes in recipient mice. Conclusion/interpretation. Lisofylline prevents the onset of autoimmune diabetes in NOD mice by a mechanism that does not seem to enhance the function of regulatory T cells, but could be associated with suppression of proinflammatory cytokines and reduction of cellular infiltration in islets. This study suggests that Lisofylline could have therapeutic benefits in preventing the onset of Type I diabetes.
         datePublished:2002-08-01T00:00:00Z
         dateModified:2002-08-01T00:00:00Z
         pageStart:1307
         pageEnd:1314
         sameAs:https://doi.org/10.1007/s00125-002-0901-y
         keywords:
            Lisofylline NOD mice macrophage IL-1β insulitis Type I diabetes mellitus
            Internal Medicine
            Metabolic Diseases
            Human Physiology
         image:
         isPartOf:
            name:Diabetologia
            issn:
               1432-0428
               0012-186X
            volumeNumber:45
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Z.-D. Yang
               affiliation:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                     address:
                        name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Chen
               affiliation:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                     address:
                        name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Wu
               affiliation:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                     address:
                        name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. McDuffie
               affiliation:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                     address:
                        name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J.-L. Nadler
               affiliation:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405
                     address:
                        name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice
      description: Aims/hypothesis. Pro-inflammatory cytokines are increased during the active stages of Type I (insulin-dependent) diabetes mellitus. The aim of this study was to investigate the applicability of using a new anti-inflammatory compound, Lisofylline, to prevent diabetes in non-obese diabetic (NOD) mice. Lisofylline has previously been shown to block Th1 cell differentiation and to reduce IL-1β-induced dysfunction in rat islets. Methods. Lisofylline was added to isolated NOD islets in vitro, with or without IL-1β. Insulin secretion and DNA damage of the islets was assessed. Lisofylline was administered to female non-obese diabetic mice starting at 4, 7 and 17 weeks of age for 3 weeks. Cytokines and blood glucose concentrations were monitored. Histology and immunohistochemistry were carried out in pancreatic sections. Splenocytes isolated from donor mice were intravenously injected into immunodeficient NOD (NOD.scid) mice. Results. In vitro, Lisofylline preserved beta-cell insulin secretion and inhibited DNA damage of islets in the presence of IL-1β. In vivo, Lisofylline suppressed IFN-γ production, reduced the onset of insulitis and diabetes, and inhibited diabetes after transfer of splenocytes from Lisofylline-treated donors to NOD.scid recipients. However, cotransfer of splenocytes from both Lisofylline-treated and diabetic NOD donors did not suppress diabetes in recipient mice. Conclusion/interpretation. Lisofylline prevents the onset of autoimmune diabetes in NOD mice by a mechanism that does not seem to enhance the function of regulatory T cells, but could be associated with suppression of proinflammatory cytokines and reduction of cellular infiltration in islets. This study suggests that Lisofylline could have therapeutic benefits in preventing the onset of Type I diabetes.
      datePublished:2002-08-01T00:00:00Z
      dateModified:2002-08-01T00:00:00Z
      pageStart:1307
      pageEnd:1314
      sameAs:https://doi.org/10.1007/s00125-002-0901-y
      keywords:
         Lisofylline NOD mice macrophage IL-1β insulitis Type I diabetes mellitus
         Internal Medicine
         Metabolic Diseases
         Human Physiology
      image:
      isPartOf:
         name:Diabetologia
         issn:
            1432-0428
            0012-186X
         volumeNumber:45
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Z.-D. Yang
            affiliation:
                  name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                  address:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Chen
            affiliation:
                  name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                  address:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Wu
            affiliation:
                  name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                  address:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. McDuffie
            affiliation:
                  name:Division of Endocrinology and Metabolism, Department of Internal Medicine
                  address:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J.-L. Nadler
            affiliation:
                  name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405
                  address:
                     name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Diabetologia
      issn:
         1432-0428
         0012-186X
      volumeNumber:45
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine
      address:
         name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
         type:PostalAddress
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine
      address:
         name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
         type:PostalAddress
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine
      address:
         name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
         type:PostalAddress
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine
      address:
         name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
         type:PostalAddress
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405
      address:
         name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Z.-D. Yang
      affiliation:
            name:Division of Endocrinology and Metabolism, Department of Internal Medicine
            address:
               name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
               type:PostalAddress
            type:Organization
      name:M. Chen
      affiliation:
            name:Division of Endocrinology and Metabolism, Department of Internal Medicine
            address:
               name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
               type:PostalAddress
            type:Organization
      name:R. Wu
      affiliation:
            name:Division of Endocrinology and Metabolism, Department of Internal Medicine
            address:
               name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
               type:PostalAddress
            type:Organization
      name:M. McDuffie
      affiliation:
            name:Division of Endocrinology and Metabolism, Department of Internal Medicine
            address:
               name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
               type:PostalAddress
            type:Organization
      name:J.-L. Nadler
      affiliation:
            name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405
            address:
               name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine, USA
      name:Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908-1405, USA

External Links {🔗}(33)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.36s.

LINK . SPRINGER . COM {}